The mechanism via which bone marrow-derived cell-expressed Cav-2 promotes tumor growth remains to be examined but could potentially involve suppression of M1 TAMs implied by our flow cytometry data demonstrating increased M1-like TAM frequency in the early stage LLC tumors with co-injected Cav-2 KO bone marrow cells. This evidence concerns the gene CAV2 and neoplasm.